REFILE-FDA declines to approve Evolus Inc's rival treatment to Botox
May 16, 2018 at 08:43 AM EDT
May 16 (Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing certain deficiencies related to its potential treatment for frown lines.
